Avadel Pharmaceuticals (AVDL – Research Report) received a Buy rating and price target from Craig-Hallum analyst Chase Knickerbocker today. The company’s shares closed yesterday at $18.18.
Knickerbocker covers the Healthcare sector, focusing on stocks such as Xtant Medical Holdings, Avadel Pharmaceuticals, and Ironwood Pharma. According to TipRanks, Knickerbocker has an average return of 5.8% and a 46.84% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Avadel Pharmaceuticals with a $24.17 average price target.
AVDL market cap is currently $1.84B and has a P/E ratio of -8.98.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avadel Pharmaceuticals (AVDL) Company Description:
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. It offers Bloxiverz, Vazculep, and Akovaz. The company was founded on December 1, 2015 and is headquartered in Dublin, Ireland.
Read More on AVDL:
- Is AVDL a Buy, Before Earnings?
- Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
- Avadel Pharmaceuticals call buyer realizes 17% same-day gains
- Avadel Pharmaceuticals Shifts to Nasdaq, Ends ADR Program
- Avadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
